Skip to main content
OpenTrials
Completed

NCT Number: NCT02445495

Chart Review of the Efficacy of the GenesisPlus 1064 nm Nd:YAG Laser in the Treatment of Onychomycosis

The purpose of this study is to determine if toenail onychomycosis can be reduced by means of exposure to laser energy from the Cutera® GenesisPlus 1064 Nd:YAG laser system.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This is a retrospective, open-label, single-centre study for the collection of clinical data on the efficacy and safety of the Cutera® GenesisPlus 1064 nm Nd:YAG laser for the treatment of nail fungus (onychomycosis). Safety and efficacy of treatment with the GenesisPlus laser will be evaluated by (1) assessment of subject's great toenail photographs at baseline and after two treatments with GenesisPlus Laser utilizing planimetry measurement of infected vs. clear nail area in target toenail photographs, (2) by clinical and subjective review of acute and follow up adverse events that may have resulted from laser treatment of the target toenails.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or Female subjects, age 18 to 80 years (inclusive).
  • Subject with a clinical diagnosis of onychomycosis of one or both great toenails at baseline.
  • Subject with a positive potassium hydroxide (KOH) stain and/or fungal culture.
  • Subject has baseline and post treatment digital photographs of target great toenails.
  • Subjects provided informed consent for treatment of nails with the Cutera GenesisPlus laser system.

Exclusion criteria

  • Subjects have received laser treatment of the infected great toenail(s) with a non-Cutera® laser system within twelve (12) months prior to Cutera® GenesisPlus laser treatment.
  • Subjects have had a history or clinical diagnosis of moccasin type tinea pedis, lichen planus, psoriasis or bacterial nail infection.
  • Subjects had a history or clinical diagnosis of coexisting disorders that may potentially demonstrate nail manifestations.
  • Systemic antifungal medication within six (6) months prior to or following Cutera® GenesisPlus laser treatment.
  • Subjects who have had a history or clinical diagnosis of repetitive nail trauma prior to treatment.
  • Subjects who have participated in any clinical research study within thirty (30) days prior to or within 210 days following final Cutera® GenesisPlus laser treatment.
  • Subjects who were pregnant or breastfeeding.

Treatment and study plan

GenesisPlus 1064 nm Nd:YAG laser

Device

Genesis Plus 1064 nm Nd: YAG laser to treat onychomycosis

Other names: Cutera®

Primary outcomes

  1. change in % of infected toenail involvement

    Time frame: change from baseline up to 6 months

    onychomycosis involvement

Sponsors and collaborators

Lead sponsor

Jason K Rivers, MD, FRCPC, FAAD

Other

Collaborators

  • Cutera Inc.

Registry information

Official study title

A Single Centre Retrospective Chart Review Study to Assess the Efficacy of the GenesisPlus 1064 nm Nd:YAG Laser in the Treatment of Onychomycosis

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
May 15, 2015
Registry last updated
May 15, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.